TranslatePriority 20 from the Advanced Heart Failure PSP
| UNCERTAINTY: Do health professionals understand the life / activity / functional consequences of each medicine? (JLA PSP Priority 20) | |
|---|---|
| Overall ranking | 20 |
| JLA question ID | 0098/20 |
| Explanatory note |
No significant evidence for people with advanced heart failure |
| Evidence |
No systematic reviews on this topic in past five years |
| Health Research Classification System category | Cardiovascular |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | [My comments are around the huge consequences of one drug over another when both are in the same class. Specifically, how bisoprolol acted like a cosh whereas carvedilol was just pulled you down a little. There seemed to be little appreciation (or sympathy) for the difference in effect, and the life consequences. Being on Bisoprolol meant I couldn't walk 50 metres without sitting on a neighbour's wall with a heaving chest. Carvedilol meant I could cycle 5km to my cardiology appointment.] In sum the question is do clinicians really appreciate the life/activity/functional consequences of one medicine over another and the effects of titration of a given drug? |
| Submitted by | 1 x patient |
| PSP information | |
|---|---|
| PSP unique ID | 0098 |
| PSP name | Advanced Heart Failure |
| Total number of uncertainties identified by this PSP. | 65 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 13 February 2019 |
